PLANO, Texas, Feb. 29, 2016 -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute Dallas Texas – to work on key elements of its new high-purity lead-212 (212Pb) production facility under construction in Plano, Texas.
|
||||||
Five teams composed of 35 students from both schools will work on design proposals for the lobby, conference room, and “monument sign” in front of the building. AREVA Med will assess the projects and select the best design for this state-of-the-art facility. The winning team will see the results of their project at the opening ceremony.
Patrick Bourdet, CEO of AREVA Med said: “This project is symbolic of AREVA Med’s innovative and collaborative spirit and, demonstrates our commitment to the local community and our willingness to facilitate exchanges between people from different cultures. This is also an excellent way for students to work on a real project and see the tangible results of their accomplishments.”
Heather Carter, Interior Design Program Coordinator at the Art Institute of Dallas, said: “Understanding global perspectives is one of the professional standards our students must meet as part of our interior design program. This collaboration with French peers will give our students an opportunity to develop their knowledge of another culture and they are excited to work with other programs and nations in blended teams. It is a very positive undertaking, and we appreciate AREVA Med for initiating it.”
Séverine Nomdedeu, Director of École Supérieure de Design Troyes, added: “Managing practical projects is at the heart of our strategy. Made possible by AREVA Med, the collaboration with the Art Institute of Dallas represents a tremendous opportunity to exchange, share, and create, and is in line with the transcultural opening that we hope to bring to our students and the way we teach design.”
More information at www.arevamed.com, http://www.groupe-esc-troyes.com/, and https://www.artinstitutes.edu/dallas/Programs/Interior-Design/447
More about AREVA Med
AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new therapies to fight cancer. AREVA Med has developed a unique process to extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells. AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform. For more information: www.arevamed.com. Follow @AREVAmed on Twitter.
Press Contacts AREVA Med Alison Tise (301) 841-1673 [email protected] @AREVAmed


Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
Meta Expands AI Training With Employee Activity Tracking Tools
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 



